Safety and Efficacy Study of Bimatoprost, Latanoprost, and Travoprost in Patients With Elevated Intraocular Pressure (IOP) and Open-angle Glaucoma (OAG)

Allergan

Status: Completed

Conditions: Open-Angle Glaucoma; Ocular Hypertension

Treatments: Drug: bimatoprost 0.03%, latanoprost 0.005%, and travoprost 0.004%

Study type: Observational

Funder types: Industry

Identifiers

NCT00716742

Pro2

Details and patient eligibility

About

To investigate the effectiveness of the newer IOP-lowering therapies, as prescribed in normal clinical practice, in larger patient numbers. Patients will be assessed at baseline, at each follow-up visit (follow-up visits are variable as per physician discretion) and at final follow-up visit.

Enrollment: 1,099 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• A diagnosis of Primary Open-Angle Glaucoma or Ocular Hypertension newly diagnosed OR presenting with insufficiently controlled IOP on current medication (in the opinion of the treating physician)
• Patient is having both eyes treated

Exclusion criteria

• Contraindications per product labelling will apply.
• Patients with any ophthalmic co-morbidity with an influence on visual field deterioration or optic nerve head damage.

Trial design

1,099 participants in 1 patient group

1

Description:

bimatoprost 0.03% latanoprost 0.005% travoprost 0.004%

Treatment:

Drug: bimatoprost 0.03%, latanoprost 0.005%, and travoprost 0.004%